We previously reported that SLC19A1 is an importer of the immunotransmitter 2'3'cyclic-GMP-AMP (cGAMP) 1 by performing a genome wide screen in U937 cells. Soon after, Lutejin et al. reported similar findings by conducting a screen in THP-1 cells 2 . While the conclusions of these two studies largely overlap, we arrived at significantly different conclusions regarding how broadly SLC19A1 is used by different cell types. Our study suggests that in addition to SLC19A1, many cultured and primary cell types use alternative, unidentified transporters to import cGAMP and other cyclic dinucleotides (CDNs). This conclusion was based on our findings that inhibition of SLC19A1 did not significantly reduce extracellular cGAMP signaling in multiple cell types, including primary CD14 + peripheral blood mononuclear cells (PBMCs) from most donors. In contrast, Luteijn et al. concluded that SLC19A1 is the major CDN importer in humans, largely based on their use of a radiolabeled [ 32 P] cGAMP uptake assay. Using this assay, they showed that inhibition of SLC19A1 abolishes [ 32 P] uptake in total PBMCs. However, they did not test whether inhibition of SLC19A1 affects extracellular cGAMP signaling in these cells. Here, we highlight an important issue with the [ 32 P] cGAMP uptake assay used by Luteijn et al. and demonstrate that measuring extracellular cGAMP signaling through the STING pathway is currently the best method for evaluating cGAMP import. We also show that inhibition of SLC19A1 has no effect on extracellular cGAMP signaling in total PBMCs, confirming that this cell type relies on other transport mechanisms for cGAMP import.
SLC19A1. Similarly, STF-1084, another ENPP1 inhibitor we developed 5 , only weakly inhibited [ 3 H] MTX uptake through SLC19A1 (Fig. 1c) . In addition, extracellular cGAMP signaling, as measured by phosphorylation of IRF3, is not inhibited by STF-1623 or STF-1084 in U937 cells, which use SLC19A1 as their primary cGAMP importer 1 (Fig. 1d) .
Given that our ENPP1 inhibitors effectively block cGAMP degradation without interfering with cGAMP uptake, we used them to evaluate [ 32 P] cGAMP uptake kinetics. In the presence of STF-1623, we found that uptake of [ 32 P] cGAMP occurred at a linear rate for at least 15 minutes ( Fig. 1e) , with uptake reaching equilibrium by 2 hours (Fig. 1f) . These results contradict the results presented in Luteijn et al., which show linear uptake kinetics for five hours 2 . Taken together, these data strongly suggest that the assay presented by Luteijn et al. primarily measured uptake of cGAMP degradation products, rather than cGAMP itself. When we reevaluated the role of SLC19A1 in PBMCs with our modified [ 32 P] cGAMP uptake assay, we found that MTX only weakly inhibits [ 32 P] cGAMP uptake in the presence of the ENPP1 inhibitors STF-1084 (donor 1) or STF-1623 (donors 2 and 3) ( Fig. 1g) , in contrast to the 80% reduction observed by Luteijn et al.
It is important to note that 1 nM of [ 32 P] cGAMP was used in this assay, while we reported that cGAMP has a Ki of ~700 μM against MTX import by SLC19A1 1 . Therefore, it is possible that that this assay is not operating at a cGAMP concentration that is relevant to cGAMP import by SLC19A1. To test this hypothesis, we performed the same uptake assay using 1 nM of [ 32 P] cGAMP in U937 cells. Indeed, [ 32 P] cGAMP uptake was not significantly affected by the addition of MTX ( Fig. 1h) . Since most cells require micromolar concentrations of extracellular cGAMP to activate STING signaling, an uptake assay of radioactive cGAMP at nanomolar concentrations is not appropriate to evaluate cGAMP transporters. Therefore, an assay that measures STING pathway activation remains the best available readout for import of extracellular cGAMP. Using this assay, we concluded that SLC19A1 is not the primary cGAMP importer in human CD14 + PBMCs 1 or in total PBMCs (Fig. 1i) . Additional studies are needed to determine the major cGAMP importer in PBMCs, as well as to identify which cell types use SLC19A1 as their primary cGAMP importer.
Methods
Cell Culture. U937 cells were maintained in RPMI (Cellgro) supplemented with 10% heat inactivated FBS (Atlanta Biologicals) and 1% penicillin-streptomycin (GIBCO). Cells were maintained in a 5% CO2 incubator at 37 °C.
Isolation of PBMCs. Buffy coat (Stanford Blood Center) was diluted 1:3 with PBS
supplemented with 2 mM EDTA. Diluted buffy coat was layered on top of 50% Percoll (GE Healthcare) containing 140 mM NaCl and centrifuged at 600 x g for 30 min. The separated PBMC layer was collected and washed once with PBS and once with RPMI before being used for uptake and cGAMP signaling experiments.
Antibodies and reagents. The following primary antibodies were purchased from Cell Signaling Technology and used at a 1:1000 dilution: IRF3 rabbit mAb (cat. #4302), pIRF3 (S396) rabbit mAb (cat. #29047), and α-tubulin mouse mAb (cat. #3873). The following secondary antibodies were purchased from LI-COR Biosciences and used at a 1:15000 dilution: 
TLC analysis of [ 32 P] cGAMP stability. 1 nM [ 32 P] cGAMP was incubated in RPMI
supplemented with 10% heat inactivated FBS and 1% penicillin-streptomycin in a 5% CO2 incubator at 37 °C for the indicated time points. At the end of this incubation period, samples were spotted onto a TLC plate and run in a solvent containing 85% ethanol and 5 mM NH4HCO3. Plates were then exposed to a Storage Phosphor Screen (Molecular Dynamics) overnight before being imaged with a Typhoon 9400 Imager (Molecular Dynamics). 
